Oxford BioDynamics (LON:OBD) Releases Quarterly Earnings Results

Oxford BioDynamics (LON:OBD) issued its quarterly earnings results on Tuesday. The biotechnology company reported GBX (0.10) earnings per share for the quarter, Digital Look Earnings reports. Oxford BioDynamics had a negative return on equity of 316.67% and a negative net margin of 1,018.54%.The business had revenue of GBX 69 million during the quarter.

Oxford BioDynamics Trading Down 31.3%

OBD stock traded down GBX 0.05 during midday trading on Tuesday, reaching GBX 0.10. The company’s stock had a trading volume of 199,230,953 shares, compared to its average volume of 16,074,189. Oxford BioDynamics has a 1 year low of GBX 0.09 and a 1 year high of GBX 0.78. The firm has a market capitalization of £4.42 million, a price-to-earnings ratio of -0.13 and a beta of 0.42. The stock has a fifty day simple moving average of GBX 0.19 and a two-hundred day simple moving average of GBX 0.23. The company has a debt-to-equity ratio of 457.97, a quick ratio of 2.80 and a current ratio of 0.88.

About Oxford BioDynamics

Oxford BioDynamics Plc is a global biotechnology company, advancing personalized healthcare by developing and commercializing precision medicine tests for life-changing diseases.

Its flagship product is EpiSwitch® CiRT (Checkpoint Inhibitor Response Test) for cancer, a predictive immune response profile for immuno-oncology (IO) checkpoint inhibitor treatments, launched in February 2022.

In March 2021, the Company launched its first commercial prognostic test, EpiSwitch® CST (Covid Severity Test) and the first commercially available microarray kit for high-resolution 3D genome profiling and biomarker discovery, EpiSwitch® Explorer Array Kit.